Effects of graded doses of testosterone on erythropoiesis in healthy young and older men - PubMed (original) (raw)

Randomized Controlled Trial

Effects of graded doses of testosterone on erythropoiesis in healthy young and older men

Andrea D Coviello et al. J Clin Endocrinol Metab. 2008 Mar.

Abstract

Context: Erythrocytosis is a dose-limiting adverse effect of testosterone therapy, especially in older men.

Objective: Our objective was to compare the dose-related changes in hemoglobin and hematocrit in young and older men and determine whether age-related differences in erythropoietic response to testosterone can be explained by changes in erythropoietin and soluble transferrin receptor (sTfR) levels.

Design: We conducted a secondary analysis of data from a testosterone dose-response study in young and older men who received long-acting GnRH agonist monthly plus one of five weekly doses of testosterone enanthate (25, 50, 125, 300, or 600 mg im) for 20 wk.

Setting: The study took place at a General Clinical Research Center.

Participants: Participants included 60 older men aged 60-75 yr and 61 young men aged 19-35 yr.

Outcome measures: Outcome measures included hematocrit and hemoglobin and serum erythropoietin and sTfR levels.

Results: Hemoglobin and hematocrit increased significantly in a linear, dose-dependent fashion in both young and older men in response to graded doses of testosterone (P<0.0001). The increases in hemoglobin and hematocrit were significantly greater in older than young men. There was no significant difference in percent change from baseline in erythropoietin or sTfR levels across groups in either young or older men. Changes in erythropoietin or sTfR levels were not significantly correlated with changes in total or free testosterone levels.

Conclusions: Testosterone has a dose-dependent stimulatory effect on erythropoiesis in men that is more pronounced in older men. The testosterone-induced rise in hemoglobin and hematocrit and age-related differences in response to testosterone therapy may be mediated by factors other than erythropoietin and sTfR.

PubMed Disclaimer

Figures

Figure 1

A, Hemoglobin in young (left panel) and older (right panel) men during the 20-wk treatment period. Data are mean ±

sem

. Hg, Hemoglobin. B, Hematocrit in young (left panel) and older (right panel) men during the 20-wk treatment period. Data are mean ±

sem

. Hct, Hematocrit. C, Mean ±

sem

percent changes in hemoglobin (Hg) in young (left panel) and older (right panel) men during testosterone treatment. D, Mean ±

sem

percent changes in hematocrit in young (left panel) and older (right panel) men during testosterone treatment. TE, Testosterone enanthate.

Figure 2

A, Serum erythropoietin (Epo) levels in young (left panel) and older (right panel) men during the 20-wk treatment period. Data are mean ±

sem

. Overall ANOVA did not reveal an age or dose effect. B, Serum sTfR levels in young (left panel) and older (right panel) men during the 20-wk treatment period. Data are mean ±

sem

. Overall ANOVA did not reveal an age or dose effect. C, Changes in serum erythropoietin levels in young (○ with dashed line) and older men (▪ with solid line) are plotted against serum total testosterone (left panel) and free testosterone (right panel) levels during testosterone treatment. There was no significant correlation between total or free testosterone and change in erythropoietin levels in either young or older men. There was no age effect on the relationship between percent change in erythropoietin levels and testosterone levels. D, Changes in serum sTfR levels in young (○ with dashed line) and older men (▪ with solid line) are plotted against serum total testosterone (left panel) and free testosterone (right panel) levels during testosterone treatment. There was no significant correlation between total or free testosterone during treatment and change in StFR levels in either young or older men. There was no age effect on the relationship between percent change in sFtR levels and testosterone levels. T, Testosterone; TE, testosterone enanthate.

References

1. Bhasin S, Cunningham GR, Hayes FJ, Matsumoto AM, Snyder PJ, Swerdloff RS, Montori VM 2006 Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91:1995–2010 - PubMed
1. Calof O, Singh AB, Lee ML, Urban RJ, Kenny AM, Tenover JL, Bhasin S 2005 Adverse events associated with testosterone supplementation of older men: a meta-analysis of randomized, placebo-controlled trials. J Gerontol A Med Sci 60:1451–1457 - PubMed
1. Jockenhovel F, Vogel E, Reinhardt W, Reinwein D 1997 Effects of various modes of androgen substitution therapy on erythropoiesis. Eur J Med Res 2:293–298 - PubMed
1. Basaria S, Dobs AS 1999 Risks versus benefits of testosterone therapy in elderly men. Drugs Aging 15:131–142 - PubMed
1. Molinari PF 1982 Erythropoietic mechanisms of androgens: a critical review and clinical implications. Haematologica 67:442–460 - PubMed

Effects of graded doses of testosterone on erythropoiesis in healthy young and older men - PubMed (original) (raw)